Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
March 3, 2026
Immuneai-CMV (Phase 1): Precision Phenotyping Reveals Heterogeneous CMV–GVHD Trade-Offs Following Allogeneic HCT
EE
Eman M. Elsabbagh
Duke University
AC
Augusto Dulanto Chiang
Vanderbilt University Medical Center
MA
Mohammad K. Alexanderani
University of Pittsburgh Medical Center
Puntos clave
The analysis uncovers heterogeneous trade-offs between CMV infection and GVHD outcomes.
Key findings highlight variable immune responses linked to CMV in a subset of patients.
Observational analysis highlights distinct immune response patterns after allogeneic hematopoietic cell transplantation.
These insights may guide personalized treatment strategies for managing CMV risks in transplant patients.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Elsabbagh et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76039c6e9836116a2cbfc
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.800
Immuneai-CMV (Phase 1): Precision Phenotyping Reveals Heterogeneous CMV–GVHD Trade-Offs Following Allogeneic HCT | Synapse